2026-05-29

CFTC GOLD speculator at extreme short — contrarian bull signal

OSINT: Russian Ruble Volatility Sparks FX Market Reaction

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC GOLD speculator at extreme short — contrarian bull signal

OSINT: Russia Boosts LNG Output 10% YoY, Expands Exports to Europe, China

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

Saudi Arabia (Dhahran): drought conditions detected — potential oil supply impact

CFTC GOLD speculator at extreme short — contrarian bull signal

OSINT: US-Iran Draft Deal Delayed After Leadership Review, NBC Reports

CFTC COPPER speculator at extreme long — contrarian bear signal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC GOLD speculator at extreme short — contrarian bull signal

Oil -1.28% — significant selloff

Gold +1.98% — significant rally

Oil -1.48% — significant selloff

Gold +1.23% — significant rally

Oil -1.87% — significant selloff

ETH open interest -64.9% — OI collapse

BTC open interest -48.0% — OI collapse

SOL open interest -27.4% — OI collapse

BTC ETF inflow of $1428M — institutional buying

ETH ETF inflow of $194M — institutional buying

ETH ETF inflow of $193M — institutional buying

BTC ETF inflow of $141M — institutional buying

SOL DEX volume/liquidity ratio elevated (0.70x) — strong on-chain trading activity

FDA approves drug (ABBOTT) — new revenue stream

FDA approves drug (ABBOTT) — new revenue stream

FDA approves drug (ABBOTT) — new revenue stream

FDA approves PROSTIN VR PEDIATRIC (PFIZER) — new revenue stream

FDA approves MEDROXYPROGESTERONE ACETATE (PFIZER) — new revenue stream

FDA approves PROSTIN VR PEDIATRIC (PFIZER) — new revenue stream

FDA approves MEDROXYPROGESTERONE ACETATE (PFIZER) — new revenue stream

FDA approves PROSTIN VR PEDIATRIC (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves MEDROXYPROGESTERONE ACETATE (PFIZER) — new revenue stream

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Activist 13D filing — engage in discussions

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

MSFT RSI 70.8 — overbought (crossed above 70)

QQQ RSI 72.4 — overbought (crossed above 70)

SPY RSI 71.2 — overbought (crossed above 70)

Beat consensus by 19.7% — EPS $-0.59 vs $-0.7344 estimate

Beat consensus by 31.1% — EPS $-0.45 vs $-0.6528 estimate

Missed consensus by 96.1% — EPS $-0.28 vs $-0.1428 estimate

Missed consensus by 233.3% — EPS $-0.68 vs $-0.204 estimate

Beat consensus by 27.7% — EPS $-1.8 vs $-2.4888 estimate

Missed consensus by 43.3% — EPS $-1.25 vs $-0.8721 estimate

Missed consensus by 7.1% — EPS $-1.53 vs $-1.428 estimate

Missed consensus by 566.7% — EPS $-0.09 vs $-0.0135 estimate

Missed consensus by 11.3% — EPS $-0.06 vs $-0.0539 estimate

Missed consensus by 98.0% — EPS $-0.06 vs $-0.0303 estimate

Beat consensus by 108.3% — EPS $0.01 vs $-0.1212 estimate

Missed consensus by 27.9% — EPS $0.86 vs $1.1923 estimate

Missed consensus by 22.2% — EPS $1.17 vs $1.5039 estimate

Missed consensus by 11.4% — EPS $1.09 vs $1.2298 estimate

Missed consensus by 298.1% — EPS $-0.67 vs $-0.1683 estimate

Beat consensus by 44.0% — EPS $-0.06 vs $-0.1071 estimate

Missed consensus by 66.9% — EPS $-0.12 vs $-0.0719 estimate

Beat consensus by 32.8% — EPS $-0.09 vs $-0.1339 estimate

Beat consensus by 186.6% — EPS $0.06 vs $-0.0693 estimate

Beat consensus by 8.2% — EPS $0.12 vs $0.1109 estimate

Beat consensus by 124.0% — EPS $0.11 vs $0.0491 estimate

Beat consensus by 5.1% — EPS $0.35 vs $0.3329 estimate

Beat consensus by 10.1% — EPS $0.25 vs $0.2271 estimate

Beat consensus by 47.7% — EPS $0.35 vs $0.237 estimate

Beat consensus by 16.2% — EPS $-5.5 vs $-6.565 estimate

Beat consensus by 8.6% — EPS $-6 vs $-6.565 estimate

Beat consensus by 7.8% — EPS $2.27 vs $2.1054 estimate

Beat consensus by 10.9% — EPS $2.09 vs $1.8847 estimate

Beat consensus by 6.4% — EPS $1.76 vs $1.6538 estimate

Beat consensus by 30.0% — EPS $2.17 vs $1.6687 estimate

Missed consensus by 52.1% — EPS $-0.47 vs $-0.309 estimate

Missed consensus by 106.3% — EPS $-5.2 vs $-2.5201 estimate

Beat consensus by 64.6% — EPS $-0.44 vs $-1.2412 estimate

Missed consensus by 853.4% — EPS $-0.44 vs $0.0584 estimate

Missed consensus by 5.6% — EPS $-0.31 vs $-0.2935 estimate

Beat consensus by 60.7% — EPS $-0.13 vs $-0.3311 estimate

Missed consensus by 6.2% — EPS $-0.32 vs $-0.3013 estimate

Missed consensus by 10.0% — EPS $-0.3 vs $-0.2728 estimate

Missed consensus by 108.3% — EPS $-0.29 vs $-0.1392 estimate

Beat consensus by 23.8% — EPS $-0.05 vs $-0.0656 estimate

Missed consensus by 39.1% — EPS $-0.08 vs $-0.0575 estimate

Missed consensus by 404.1% — EPS $-0.92 vs $-0.1825 estimate

Beat consensus by 6.0% — EPS $0.47 vs $0.4434 estimate

Missed consensus by 38.3% — EPS $0.25 vs $0.4049 estimate

Missed consensus by 7.8% — EPS $0.42 vs $0.4553 estimate

Beat consensus by 9.0% — EPS $2.86 vs $2.6232 estimate

Missed consensus by 16.3% — EPS $0.1 vs $0.1195 estimate

Beat consensus by 100.0% — EPS $0 vs $-0.0102 estimate

Beat consensus by 281.2% — EPS $0.17 vs $0.0446 estimate

Beat consensus by 106.2% — EPS $0.08 vs $0.0388 estimate

Beat consensus by 10.8% — EPS $2.62 vs $2.3636 estimate

Beat consensus by 11.9% — EPS $3.04 vs $2.7166 estimate

Beat consensus by 9.4% — EPS $2.5 vs $2.2855 estimate

Beat consensus by 15.5% — EPS $3.09 vs $2.6752 estimate

Missed consensus by 11.2% — EPS $0.79 vs $0.8901 estimate

Beat consensus by 10.8% — EPS $0.47 vs $0.4241 estimate

Beat consensus by 13.7% — EPS $0.33 vs $0.2902 estimate

Beat consensus by 21.9% — EPS $0.38 vs $0.3118 estimate

Missed consensus by 30.3% — EPS $69.68 vs $99.99 estimate

Beat consensus by 193.3% — EPS $13.19 vs $-14.14 estimate

Missed consensus by 17.1% — EPS $47.75 vs $57.57 estimate

Missed consensus by 52.4% — EPS $-50.78 vs $-33.33 estimate

Beat consensus by 5.7% — EPS $2.7 vs $2.5553 estimate

Missed consensus by 375.2% — EPS $-0.48 vs $-0.101 estimate

Beat consensus by 37.0% — EPS $-0.14 vs $-0.2222 estimate

Missed consensus by 218.5% — EPS $-0.15 vs $-0.0471 estimate

Missed consensus by 122.8% — EPS $-0.18 vs $-0.0808 estimate

Beat consensus by 5.2% — EPS $2.78 vs $2.6428 estimate

Beat consensus by 6.1% — EPS $3.22 vs $3.034 estimate

Beat consensus by 5.9% — EPS $3.15 vs $2.9742 estimate

Missed consensus by 7.8% — EPS $-16.5 vs $-15.3 estimate

Beat consensus by 26.5% — EPS $-4.5 vs $-6.12 estimate

Missed consensus by 17.6% — EPS $-9 vs $-7.65 estimate

Beat consensus by 21.6% — EPS $-6 vs $-7.65 estimate

Beat consensus by 16.0% — EPS $0.55 vs $0.4743 estimate

Missed consensus by 25.8% — EPS $0.43 vs $0.5794 estimate

Beat consensus by 19.8% — EPS $0.29 vs $0.2421 estimate

Beat consensus by 6.3% — EPS $0.23 vs $0.2163 estimate

Beat consensus by 50.5% — EPS $-0.02 vs $-0.0404 estimate

Beat consensus by 34.0% — EPS $-0.02 vs $-0.0303 estimate

Beat consensus by 40.6% — EPS $-0.03 vs $-0.0505 estimate

Beat consensus by 15.4% — EPS $1.96 vs $1.6984 estimate

Beat consensus by 25.8% — EPS $2.13 vs $1.6935 estimate

Beat consensus by 10.2% — EPS $2.04 vs $1.8506 estimate

Beat consensus by 20.7% — EPS $1.84 vs $1.5247 estimate

Beat consensus by 246.5% — EPS $0.35 vs $0.101 estimate

Missed consensus by 58.3% — EPS $0.08 vs $0.1919 estimate

Beat consensus by 18.8% — EPS $0.1 vs $0.0842 estimate

Beat consensus by 293.3% — EPS $0.47 vs $0.1195 estimate

Missed consensus by 6.1% — EPS $3.98 vs $4.2381 estimate

Missed consensus by 6.7% — EPS $4.524 vs $4.8468 estimate

Missed consensus by 11.6% — EPS $1.68 vs $1.8999 estimate

Beat consensus by 9.3% — EPS $1.87 vs $1.7104 estimate

Beat consensus by 9.7% — EPS $2 vs $1.823 estimate

Beat consensus by 5.7% — EPS $1.93 vs $1.8251 estimate

Beat consensus by 10.1% — EPS $1.27 vs $1.1531 estimate

Beat consensus by 12.2% — EPS $1.68 vs $1.4969 estimate

Beat consensus by 19.4% — EPS $1.5 vs $1.2568 estimate

Beat consensus by 6.8% — EPS $1.37 vs $1.2829 estimate

Missed consensus by 412.4% — EPS $-1.03 vs $0.3297 estimate

Missed consensus by 6.0% — EPS $0.15 vs $0.1596 estimate

Missed consensus by 27.2% — EPS $0.26 vs $0.3573 estimate

Missed consensus by 18.8% — EPS $0.24 vs $0.2956 estimate

Missed consensus by 27.4% — EPS $0.2 vs $0.2754 estimate

Missed consensus by 15.0% — EPS $0.26 vs $0.306 estimate

Missed consensus by 31.8% — EPS $0.16 vs $0.2346 estimate

Beat consensus by 23.6% — EPS $1.05 vs $0.8498 estimate

Missed consensus by 5.4% — EPS $0.38 vs $0.4017 estimate

Missed consensus by 39.0% — EPS $0.27 vs $0.4429 estimate

Missed consensus by 96.1% — EPS $-0.01 vs $-0.0051 estimate

DXY RSI 71.5 — overbought (crossed above 70)